Teva Pharmaceutical Industries (TEVA) Profit After Tax (2016 - 2025)
Historic Profit After Tax for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $481.0 million.
- Teva Pharmaceutical Industries' Profit After Tax fell 8679.66% to $481.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.4 billion, marking a year-over-year decrease of 2587.56%. This contributed to the annual value of $1.4 billion for FY2025, which is 2761.61% down from last year.
- Per Teva Pharmaceutical Industries' latest filing, its Profit After Tax stood at $481.0 million for Q4 2025, which was down 8679.66% from $434.0 million recorded in Q3 2025.
- Teva Pharmaceutical Industries' 5-year Profit After Tax high stood at $3.6 billion for Q4 2024, and its period low was -$1.3 billion during Q4 2022.
- Moreover, its 5-year median value for Profit After Tax was $70.0 million (2022), whereas its average is $94.9 million.
- As far as peak fluctuations go, Teva Pharmaceutical Industries' Profit After Tax plummeted by 123690.48% in 2022, and later surged by 22730.68% in 2023.
- Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Profit After Tax stood at -$152.0 million in 2021, then crashed by 776.97% to -$1.3 billion in 2022, then skyrocketed by 227.31% to $1.7 billion in 2023, then soared by 114.67% to $3.6 billion in 2024, then crashed by 86.8% to $481.0 million in 2025.
- Its Profit After Tax stands at $481.0 million for Q4 2025, versus $434.0 million for Q3 2025 and $283.0 million for Q2 2025.